WP1301 / Worg Pharma - LARVOL DELTA

Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice. (PubMed, Blood Adv) - "Here, we report a peptide-based, antigen-specific immunotherapy designed to specifically re-establish immune tolerance to FVIII through the development of antigen-processing-independent epitopes (apitopes). Furthermore, treatment with ATX-F8-117 significantly reduced FVIII inhibitor formation. ATX-F8-117 regulates both anti-FVIII T cell and B cell responses, specifically the generation of FVIII inhibitors, revealing peptide-based antigen-specific immunotherapy as a promising approach to both suppress and treat inhibitor formation in susceptible HA patients."

Journal • Preclinical • Hematological Disorders • Hemophilia • Immunology • Rare Diseases • Thrombosis • CD4 • HLA-DRB1

Apitope raises €12 million in series B funding to progress treatments for autoimmune diseases (PRNewswire) - "Apitope...today announces it has successfully raised €12 million in a Series B financing. The funds will enable Apitope to progress the clinical development of its innovative pipeline which includes therapies for Factor VIII intolerance in Haemophilia A patients and Graves' disease. Apitope will relocate its UK headquarters to Wales. The funding will enable us to progress development of our product ATX-F8-117, which received Orphan Drug Designation from both the US FDA and the EMA highlighting the need for an effective treatment for Haemophilia A patients developing Factor VIII inhibitors."

Financing • Hemophilia